SINOMAB BIO-B (03681): Xue Lei has been appointed as a non-executive director.
China Antibody-B (03681) issued an announcement that, after being approved at the 2026 annual shareholders' meeting, Ms. Xue Lei (Ms. Xue) has been appointed as a non-executive director, effective at the end of the 2026 annual shareholders' meeting.
SINOMAB BIO-B (03681) announced that Ms. Xue Lei (Ms. Xue) has been appointed as a non-executive director, effective upon approval at the 2026 annual shareholders' meeting.
Related Articles
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
RECOMMEND
